drugset / Trial / NCT04626414

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

NCT04626414

Phase 1 Completed 32 enrolled Shield Therapeutics
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of the study is to compare the Pharmacokinetics (PK) of the new ferric maltol suspension, in adults, with the existing ferric maltol capsule.

Timeline

Start
2020-09-28
Primary completion
2020-11-13
Completion
2020-11-13

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric maltol Small molecule 30 mg